Volver a Agenda
Session Chair(s)
Joseph A DiMasi, PHD
Director of Economic Analysis and Research Associate Professor
Tufts Center for the Study of Drug Development, United States
Learning Objective : Analyze the historical record concerning technical risks in clinical development of new drugs and biologics; Assess how clinical, compound, operational, and economic characteristics can be used to make better go/no-go development decisions.
Speaker(s)
APGAR Begets ANDI: What Drug Developers Can Learn from Orchestra Auditions and Crying Newborns
Wayne Rackoff, MD, MA
Janssen Research & Development, LLC, United States
Vice President, Clinical Oncology
Improving Phase 2 Go/No-Go Decision-Making with a Simple Scoring Algorithm
Joseph A DiMasi, PHD
Tufts Center for the Study of Drug Development, United States
Director of Economic Analysis and Research Associate Professor
Looking at Cost/Time/Risk/Value Scenarios to Improve Clinical Program Decision-Making
Rick Sax, DrMed, FACP
Pharma Design Solutions, Ltd., United Kingdom
Managing Director
¿Tiene una cuenta?